Skip to content

Impact of using an automatic bolus calculator for glycemic control in patients with type 1 diabetes mellitus

Impact of using an Automatic Bolus Calculator for glycemic control in patients with type 1 Diabetes Mellitus receiving multiple daily Insulin injections

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7nw8wz
Enrollment
Unknown
Registered
2018-08-06
Start date
2016-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

The 26 patients were separated into two groups (Figure 1). If their mobile phone was compatible with the Accu-Chek Connect smartphone app, they were assigned to the Intervention (Connect) group (n=13)
Device

Sponsors

Irmandade Santa Casa de Misericordia de Sao Paulo
Lead Sponsor
Irmandade Santa Casa de Misericordia de Sao Paulo
Collaborator

Eligibility

Age
17 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients >16 years old; HbA1c over ou equal to 6.5%; T1DM diagnosis for more than 1 year; being treated with multiple daily insulin injections (MDI); pre-prandial insulin doses adjusted according to carbohydrate count

Exclusion criteria

Exclusion criteria: T2DM or T1DM diagnosis for less than 1 year from the screening date; use of oral hypoglycemic agents, apart from metformin; fixed insulin injections; or using insulin dosage tables according to their blood glucose tests.

Design outcomes

Primary

MeasureTime frame
The study assessed the impact of the Accu-Chek Performa blood glucometer with automatic bolus calculator (ABC) on glycemic control in T1DM patients, according to the HbA1c evaluation.

Secondary

MeasureTime frame
The study assessed the impact of the Accu-Chek Performa blood glucometer with automatic bolus calculator (ABC) on glycemic parameters (estimated mean glycemia and percentage of hyperglycemia, normoglycemia and hypoglycemia), on glycemic variability (glycemia standard deviation) and on treatment compliance (numbers of tests/day and boluses/day).

Countries

Brazil

Contacts

Public ContactCecilia K R Feder

Irmandade Santa Casa de Misericordia de Sao Paulo

draceciliafeder@gmail.com+55-11-982921793

Outcome results

None listed

Source: REBEC (via WHO ICTRP)